VEGFA and lung cancer: Methyl syringate inhibited hypoxia-induced COX-2 expression and promoter activity, reduced hypoxia-induced lung cancer cell migration and invasion, and inhibited vascular endothelial growth factor secretion (Park et al., 2016).